Summary of Evan Hughes's The Hard Sell (eBook, ePUB)
PAYBACK Punkte
1 °P sammeln!
Please note: This is a companion version & not the original book. Book Preview:#1 Mike Babich was a wealth manager at Northern Trust, a Chicago banking institution, who was offered a job by a high-net-worth individual in the pharmaceutical business. He didn't know much about his client, but he accepted the offer.#2 Kapoor was a pharmaceutical industry mogul who made his fortune by developing generic medications. He was the largest shareholder in at least five companies. He had made a fortune as a biotech entrepreneur.#3 Kapoor's company, Lypho-Med, was a powerhouse in the generic drug business...
Please note: This is a companion version & not the original book. Book Preview:
#1 Mike Babich was a wealth manager at Northern Trust, a Chicago banking institution, who was offered a job by a high-net-worth individual in the pharmaceutical business. He didn't know much about his client, but he accepted the offer.
#2 Kapoor was a pharmaceutical industry mogul who made his fortune by developing generic medications. He was the largest shareholder in at least five companies. He had made a fortune as a biotech entrepreneur.
#3 Kapoor's company, Lypho-Med, was a powerhouse in the generic drug business. In the 1980s, government incentives favored cheaper alternatives to branded medications. Kapoor was a consistent winner, and his company grew rapidly under his ownership.
#4 After the acquisition, Lyphomed's value and reputation were destroyed. In 1992, Fujisawa sued Kapoor, alleging that he had concealed devastating FDA problems during the sale. The buyer was accusing Kapoor of selling a lemon.
#1 Mike Babich was a wealth manager at Northern Trust, a Chicago banking institution, who was offered a job by a high-net-worth individual in the pharmaceutical business. He didn't know much about his client, but he accepted the offer.
#2 Kapoor was a pharmaceutical industry mogul who made his fortune by developing generic medications. He was the largest shareholder in at least five companies. He had made a fortune as a biotech entrepreneur.
#3 Kapoor's company, Lypho-Med, was a powerhouse in the generic drug business. In the 1980s, government incentives favored cheaper alternatives to branded medications. Kapoor was a consistent winner, and his company grew rapidly under his ownership.
#4 After the acquisition, Lyphomed's value and reputation were destroyed. In 1992, Fujisawa sued Kapoor, alleging that he had concealed devastating FDA problems during the sale. The buyer was accusing Kapoor of selling a lemon.
Dieser Download kann aus rechtlichen Gründen nur mit Rechnungsadresse in A, B, BG, CY, CZ, D, DK, EW, E, FIN, F, GR, HR, H, IRL, I, LT, L, LR, M, NL, PL, P, R, S, SLO, SK ausgeliefert werden.
Andere Kunden interessierten sich für
